Squarepoint’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.47M | Buy |
+8,419
| New | +$2.39M | ﹤0.01% | 2179 |
|
|
2026
Q1 | – | Sell |
-5,425
| Closed | -$1.64M | – | 4286 |
|
|
2025
Q4 | $1.64M | Sell |
5,425
-49,310
| -90% | -$15.4M | ﹤0.01% | 2188 |
|
|
2025
Q3 | $15.3M | Buy |
+54,735
| New | +$14.9M | 0.02% | 876 |
|
|
2025
Q1 | – | Sell |
-13,174
| Closed | -$4.33M | – | 4598 |
|
|
2024
Q4 | $4.33M | Sell |
13,174
-8,712
| -40% | -$2.96M | ﹤0.01% | 1758 |
|
|
2024
Q3 | $7.32M | Sell |
21,886
-4,025
| -16% | -$1.28M | 0.01% | 1161 |
|
|
2024
Q2 | $7.08M | Sell |
25,911
-34,691
| -57% | -$10.1M | 0.01% | 1137 |
|
|
2024
Q1 | $21M | Sell |
60,602
-78,525
| -56% | -$25.8M | 0.04% | 597 |
|
|
2023
Q4 | $44.9M | Buy |
139,127
+98,098
| +239% | +$30.7M | 0.09% | 259 |
|
|
2023
Q3 | $14.7M | Buy |
41,029
+11,122
| +37% | +$4.29M | 0.04% | 595 |
|
|
2023
Q2 | $11.3M | Buy |
+29,907
| New | +$12.2M | 0.03% | 596 |
|
|
2022
Q2 | – | Sell |
-24,482
| Closed | -$13.8M | – | 2887 |
|
|
2022
Q1 | $13.8M | Buy |
24,482
+12,413
| +103% | +$7.48M | 0.06% | 353 |
|
|
2021
Q4 | $9.12M | Buy |
12,069
+9,807
| +434% | +$7.34M | 0.02% | 555 |
|
|
2021
Q3 | $1.69M | Sell |
2,262
-5,255
| -70% | -$3.94M | ﹤0.01% | 1290 |
|
|
2021
Q2 | $4.84M | Sell |
7,517
-10,598
| -59% | -$6.45M | 0.02% | 738 |
|
|
2021
Q1 | $10.3M | Buy |
18,115
+17,430
| +2,545% | +$10.3M | 0.06% | 363 |
|
|
2020
Q4 | $399K | Sell |
685
-899
| -57% | -$512K | ﹤0.01% | 1984 |
|
|
2020
Q3 | $816K | Sell |
1,584
-17,884
| -92% | -$9.06M | 0.01% | 1098 |
|
|
2020
Q2 | $8.79M | Buy |
19,468
+6,030
| +45% | +$2.66M | 0.14% | 195 |
|
|
2020
Q1 | $4.71M | Buy |
13,438
+819
| +6% | +$301K | 0.12% | 217 |
|
|
2019
Q4 | $4.67M | Sell |
12,619
-44,667
| -78% | -$15.7M | 0.03% | 529 |
|
|
2019
Q3 | $19.1M | Buy |
+57,286
| New | +$18.7M | 0.17% | 143 |
|
|
2019
Q2 | – | Sell |
-36,892
| Closed | -$11.3M | – | 2375 |
|
|
2019
Q1 | $11.3M | Buy |
+36,892
| New | +$9.96M | 0.12% | 207 |
|
|
2018
Q4 | – | Sell |
-3,166
| Closed | -$991K | – | 1935 |
|
|
2018
Q3 | $991K | Sell |
3,166
-8,337
| -72% | -$2.59M | 0.01% | 991 |
|
|
2018
Q2 | $3.32M | Buy |
11,503
+3,088
| +37% | +$853K | 0.04% | 494 |
|
|
2018
Q1 | $2.1M | Buy |
8,415
+4,614
| +121% | +$1.17M | 0.03% | 561 |
|
|
2017
Q4 | $907K | Buy |
3,801
+915
| +32% | +$222K | 0.02% | 874 |
|
|
2017
Q3 | $641K | Buy |
2,886
+911
| +46% | +$205K | 0.01% | 886 |
|
|
2017
Q2 | $447K | Buy |
+1,975
| New | +$430K | 0.01% | 1007 |
|
|
2016
Q2 | – | Sell |
-5,169
| Closed | -$707K | – | 1106 |
|
|
2016
Q1 | $707K | Buy |
5,169
+2,940
| +132% | +$386K | 0.05% | 485 |
|
|
2015
Q4 | $309K | Buy |
+2,229
| New | +$309K | 0.03% | 783 |
|
|
2015
Q2 | – | Sell |
-4,372
| Closed | -$591K | – | 466 |
|
|
2015
Q1 | $591K | Buy |
+4,372
| New | +$542K | 0.21% | 160 |
|
Other funds holding BIO
AI
Squarepoint's BIO Position: Q2 2026 in Review
Squarepoint opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 8,419 shares worth $2.47M. The stake represents ﹤0.01% of the portfolio and ranks #2179 among its holdings. This is a return to the name: Squarepoint previously reported a position in BIO as recently as Q4 2025.
Squarepoint first reported a position in BIO in Q1 2015 and has held it in 31 quarters since. The position peaked at $44.9M in Q4 2023. 397 funds tracked by Wall St. Rank hold BIO as of Q2 2026.
- Squarepoint held 8,419 shares of Bio-Rad Laboratories Class A worth $2.47M as of Q2 2026.
- Bio-Rad Laboratories Class A was a new Squarepoint position in Q2 2026.
- Bio-Rad Laboratories Class A made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2179 holding.
- Squarepoint first reported a position in Bio-Rad Laboratories Class A in Q1 2015 and has held it in 31 quarters since.
- Squarepoint's Bio-Rad Laboratories Class A position peaked at $44.9M in Q4 2023.
- 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.